
NYSEHealthcareMedical - Care Facilities
ข้อมูลล่าสุด
US$179.25
+US$2.23 · +1.26%
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
ราคาปิดก่อนหน้า
US$179.25
+US$2.23 · +1.26%
หลังปิดตลาด
US$179.25
US$0.00 · 0.00%
9 ต.ค. 16:12 ET
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
ช่วงราคารายวัน
ปัจจุบัน US$179.25
ช่วง 52 สัปดาห์
ปัจจุบัน US$179.25
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
54
มูลค่ายุติธรรม
ความเชื่อมั่น
60
ผสม
ความเสี่ยง
20
ความเสี่ยงต่ำ
โมเมนตัม
72
กำลังแข็งแกร่งขึ้น
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
ช่วงราคารายวัน
ปัจจุบัน US$179.25
ช่วง 52 สัปดาห์
ปัจจุบัน US$179.25
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 13.64B USD | 12.82B USD | 12.14B USD | 11.61B USD | 11.62B USD |
| ต้นทุนสินค้าขาย | 9.96B USD | 8.6B USD | 8.32B USD | 8.21B USD | 7.97B USD |
| กำไรขั้นต้น | 3.68B USD | 4.22B USD | 3.82B USD | 3.4B USD | 3.65B USD |
| การขาย ทั่วไป และธุรการ | 1.67B USD | 1.54B USD | 1.47B USD | 1.36B USD | 1.2B USD |
| ค่าใช้จ่ายในการดำเนินงาน | 1.67B USD | 2.13B USD | 2.22B USD | 2.06B USD | 1.85B USD |
| ดอกเบี้ยจ่าย | 549.67M USD | 470.47M USD | 398.55M USD | 357.02M USD | 285.25M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 715.35M USD | 723.86M USD | 745.44M USD | 732.6M USD | 680.62M USD |
| รายได้จากการดำเนินงาน | 2.01B USD | 2.09B USD | 1.6B USD | 1.34B USD | 1.8B USD |
| รายได้สุทธิ | 746.8M USD | 936.34M USD | 691.54M USD | 560.4M USD | 978.45M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 10 ต.ค. 2569.
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$235.67
โอกาสปรับขึ้น 31.48%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
State Street SPDR S&P 500 ETF1557.T11.63B0.01%129.34T JPY0.09%¥122,850+0.12%
Invesco S&P 500 Equal Weight ETFRSP188.8M0.20%96.75B USD0.20%US$213.04+0.55%
Vanguard Morningstar Total Stock Market ETFVTI179.76M0.01%2.3T USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO150M0.01%1.8T USD0.03%US$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB130.08M0.07%185.3B USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR82.56M0.12%68.2B USD0.05%US$234.43+0.22%
iShares Core S&P 500 ETFIVV79.63M0.01%892.79B USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY73.5M0.01%817.2B USD0.09%US$778.57+0.60%
State Street SPDR S&P 500 ETF1557.T
Invesco S&P 500 Equal Weight ETFRSP
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPYเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน